<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00242931</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000447211</org_study_id>
    <secondary_id>OHSU-SOL-04109-L</secondary_id>
    <secondary_id>OHSU-373</secondary_id>
    <nct_id>NCT00242931</nct_id>
  </id_info>
  <brief_title>Flu/TBI in Treating Patients Not Responding to Previous Hormone Therapy</brief_title>
  <official_title>Pilot Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Hormone-Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy
      before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune system and help destroy any remaining cancer cells
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an
      immune response against the body's normal cells. Giving cyclosporine and mycophenolate
      mofetil after transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well giving fludarabine together with total-body
      irradiation works in treating patients who are undergoing a donor stem cell transplant for
      progressive metastatic prostate cancer that has not responded to previous hormone therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the treatment-related mortality in patients with hormone-refractory,
           progressive metastatic prostate cancer treated with nonmyeloablative conditioning
           comprising fludarabine and total-body irradiation followed by allogeneic hematopoietic
           stem cell transplantation.

      OUTLINE:

        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine IV on days -4 to -2
           and total-body irradiation (TBI) on day 0.

        -  Allogeneic hematopoietic stem cell transplantation (AHSCT): After TBI, patients undergo
           AHSCT on day 0.

        -  Immunosuppression: Patients receive oral cyclosporine twice daily on days -3 to 56
           followed by a taper until day 81. Patients also receive oral mycophenolate mofetil twice
           daily on days 0-27 (if patient has a related donor) OR three times daily on days 0-29
           and then twice daily on days 30-149 followed by additional tapering until day 180 (if
           patient has an unrelated donor).

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to successfully recruit subjects to this study.
  </why_stopped>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related mortality as measured by Kaplan-Meier at 5 years following transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety by CTCAE v 3.0 at 100 days following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate by RECIST criteria at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression by Kaplan-Meier at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival by Kaplan-Meier at 5 years following transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response as measured by a 50% reduction in the prostate-specific antigen at 5 years following transplant</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Fludarabine, TBI, Cyclosporine, MMF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nonmyeloablative stem cell conditioning regimen</intervention_name>
    <description>Conditioning:
Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0
Hematopoeitic Stem Cell Transplantation:
Infusion of peripheral blood stem cells, day 0
Immunosuppression:
For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181.</description>
    <arm_group_label>Fludarabine, TBI, Cyclosporine, MMF</arm_group_label>
    <other_name>Mini Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of adenocarcinoma of the prostate

               -  Metastatic and progressive disease

               -  Refractory to hormonal therapy

          -  Prostate-specific antigen (PSA) &gt; 5 ng/mL

          -  Previously treated with a docetaxel-based regimen

          -  No CNS metastases

        PATIENT CHARACTERISTICS:

        Performance status

          -  Karnofsky 70-100%

        Life expectancy

          -  More than 6 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin &lt; 2 times upper limit of normal (ULN)

          -  AST and ALT &lt; 4 times ULN

        Renal

          -  Creatinine clearance &gt; 50 mL/min

        Cardiovascular

          -  LVEF &gt; 35%

          -  No symptomatic congestive heart failure

        Pulmonary

          -  DLCO &gt; 40% of predicted OR

          -  Total lung capacity or FEV_1 &gt; 30% of predicted

        Other

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  See Disease Characteristics

        PATIENT AND DONOR SELECTION CRITERIA

        4.1 Patient Inclusion Criteria:

        4.1.1 Males aged 18-75.

        4.1.2 Pathologically proven adenocarcinoma of the prostate with metastases and progressive
        disease (new metastatic lesions or increase in cancer-related pain or a rising PSA defined
        by consensus criteria. (A rising PSA will be defined as 2 measurements higher than an
        initial value. The second of the 3 measurements must be at least 7 days after the first).

        4.1.3 Progressive disease despite hormonal management (including antiandrogen withdrawal, 6
        weeks for bicalutamide, 4 weeks for flutamide or nilutamide)

        4.1.4 PSA &gt; 5 ng/mL

        4.1.5 Serum testosterone level &lt; 50 ng/mL

        4.1.6 Prior treatment with a docetaxel-based regimen.

        4.1.7 Performance status: Karnofsky Performance Scale (KPS) 70-100%. (Appendix III).

        4.1.8 Signed informed patient consent.

        4.2 Patient Exclusion criteria:

        4.2.1 Expected survival less than 6 months

        4.2.2 Active central nervous system involvement or spinal instability

        4.2.3 Organ dysfunction:

        4.2.3.1 Cardiac: Ejection fraction &lt;35% or symptomatic congestive heart failure.

        4.2.3.2 Pulmonary: DLCO &lt;40% of predicted or either TLC or FEV1 &lt; 30% predicted.

        4.2.3.3 Liver dysfunction: serum total bilirubin &gt;2x upper limit of normal (ULN) or either
        ALT or AST &gt;4x ULN

        4.2.3.4 Renal dysfunction: creatinine clearance &lt; 50 ml/min

        4.2.4 HIV seropositivity

        4.2 Related Donor Inclusion criteria:

        4.3.1 Age 18-75

        4.3.2 Related to the patient and genotypically or phenotypically HLA-identical. (Appendix
        IV)

        4.3.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and
        apheresis collection. Bone marrow donors are not eligible.

        4.3 Unrelated Donor Inclusion criteria:

        4.4.1 Age 18-75.

        4.4.2 Unrelated donors who are prospectively:

        4.4.2.1 Matched for HLA-DRB1 and -DQB1 alleles by high resolution typing AND 4.4.2.2
        Matched for all serologically recognized HLA-A or -B or -C antigens and at least five of
        six HLA-A or -B or -C alleles as defined by Appendix IV.

        4.4.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and
        apheresis collection. Bone marrow unrelated donors are not eligible.

        4.4 Related and Unrelated Donor Exclusion criteria:

        4.5.1 Identical twin.

        4.5.2 Any contraindication to the administration of G-CSF for mobilization.

        4.5.3 Serious medical or psychological illness.

        4.5.4 Prior malignancy within the preceding five years, with the exception of non-melanoma
        skin cancers.

        4.5.5 HIV seropositivity.

        4.5.6 The donor is pregnant, has a positive serum ÃŸhCG or is lactating.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon M. Hayes-Lattin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2005</study_first_submitted>
  <study_first_submitted_qc>October 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2005</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

